October 17th 2024
Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.
September 23rd 2024
September 18th 2024
Community Oncology Connections™: Selecting and Sequencing Therapy for Patients With DLBCL in an Era of Expanding Options
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
A Pilot Study of Rituximab in Patients With Relapsed Hodgkin’s Disease of Classical Type
March 1st 2001We have previously reported that normal B lymphocytes in lymph nodes and peripheral blood of patients with Hodgkin’s disease (HD) express CD40 ligand (CD40L) and CD30 ligand (CD30L). Both ligands can activate NF-kb and promote
Hodgkin's Disease on the Increase in Patients With HIV
March 1st 2001SAN FRANCISCO-An Italian study has found that Hodgkin’s disease is becoming more frequent than non-Hodgkin’s lymphoma (NHL) in people with HIV. The researchers speculate that this rise in Hodgkin’s disease may be due to the advent of highly active antiretro-viral therapy (HAART). Alessandro Re, MD, of the Universita di Brescia, presented the results at the American Society of Hematology annual meeting.
Rituximab Is Active in Lymphocyte-Predominant Hodgkin’s Disease
March 1st 2001We designed a phase II trial to determine the efficacy of the chimeric anti-CD20 monoclonal antibody rituximab (Rituxan) in lymphocyte-predominant Hodgkin’s disease (LPHD). A unique subtype of Hodgkin’s disease that expresses the CD20
Ibritumomab Tiuxetan Radioimmunotherapy of Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma
March 1st 2001Ibritumomab tiuxetan (Zevalin) is an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan, which forms a strong chelate with the pure beta-emitting isotope yttrium-90. We conducted an open-label trial of
Chemoimmunotherapy Nudges Failure-Free Survival Upward in Advanced Follicular NHL
February 1st 2001HOUSTON-Chemoimmunotherapy with rituximab (Rituxan) plus fludarabine, novantrone (mitoxantrone), and dexamethasone (FND) reduced levels of a major tumor marker and significantly improved projected 2-year failure-free survival in patients with stage IV indolent follicular non-Hodgkin’s lymphomas (NHL) who had molecular responses after 6 months of treatment. Results from a randomized study of 134 previously untreated patients were presented by Fernando F. Cabanillas, MD, chairman of the Department of Lymphoma-Myeloma at the University of Texas M. D. Anderson Cancer Center in Houston.
Rituximab Is Highly Active in Lymphocyte Predominance Hodgkin’s Disease
February 1st 2001STANFORD, California-Rituximab (Rituxan) is highly active in achieving clinical response in lymphoctye predominance Hodgkin’s disease (LPHD) and may ultimately have the potential of reducing long-term side effects and improving survival in this disease, according to the results of a phase-II trial. Although LPHD has effectively been treated with radiotherapy, chemotherapy, or a combined modality, a subset of patients experiences recurrence and treatment related morbidity and mortality-often from heart disease.
Removing B Cells May Improve Hodgkin’s Disease Response
February 1st 2001HOUSTON-Removing B cells improves control of classic Hodgkin’s disease and relieves B symptoms, reported Anas Younes, MD. Dr. Younes, associate professor, Department of Lymphoma/Myeloma at the University of Texas M. D. Anderson Cancer Center, Houston, Texas, administered the anti-CD20 monoclonal antibody rituximab (Rituxan) to heavily pretreated patients who had relapsed classic Hodgkin’s disease. The rationale behind this trial, according to Dr.Younes, was that B cells may provide survival and resistance signals to Reed-Sternberg (RS) cells in Hodgkin’s disease.
STI571 Studies Help Validate Molecular Targeting in CML
January 1st 2001NEW YORK-The promise of molecularly targeted therapies has been validated in chronic myelogenous leukemia (CML), Brian J. Druker, MD, of Oregon Health Sciences University, Portland, said at the Chemotherapy Foundation Symposium XVIII. "This disease has provided an ideal opportunity to test the concept that drugs targeted against a tumor-specific abnormality will have therapeutic utility," he said.
Outpatient Mylotarg Therapy Cuts Costs in Relapsed AML
January 1st 2001SAN FRANCISCO-Patients receiving monoclonal antibody-targeted chemotherapy with gemtuzumab ozo-gamicin (Mylotarg) rather than conventional combination chemotherapy for first relapse of acute myelogenous leukemia (AML) are more likely to be treated as outpatients, resulting in considerable cost savings, according to a study from Fred Hutchinson Cancer Research Center and Wyeth-Ayerst Research.
STI571 Proves Effective in Patients With Interferon-Failure CML
January 1st 2001SAN FRANCISCO-Results of a phase II, open-label, multicenter study show that the investigational agent STI571 holds promise for many patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) whose disease has proved resistant to interferon therapy.
Intensive Chemo for HIV+ Burkitt’s Lymphoma Patients
January 1st 2001SAN FRANCISCO-HIV-positive patients with Burkitt’s lymphoma treated with intensive chemotherapy achieved high complete response rates similar to those without HIV infection, according to a retrospective review of 38 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1988 and 2000.
Commentary (Wakoff/Porter): The Biology and Treatment of Chronic Myelogenous Leukemia
January 1st 2001Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to
Commentary (O’Brien): The Biology and Treatment of Chronic Myelogenous Leukemia
January 1st 2001Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to
Rituximab More Effective in B-Cell NHL Than in MCL
November 1st 2000NEW ORLEANS-Rituximab (Rituxan) is more effective in indolent B-cell non-Hodgkin’s Lymphoma (NHL) than in mantle cell lymphoma (MCL), according to a study evaluating factors affecting toxicity, response, and time to progression presented at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Tositumomab Effective for Low-Grade Follicular Lymphoma
July 1st 2000ASCO-Tositumomab (Bexxar), an investigational antibody-based radioim-munotherapy agent, has been shown to be effective as first-line treatment of advanced-stage, low-grade follicular lymphoma, Mark Kaminski, MD, said at the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans.
STI-571 Targets More Advanced-Stage CML and Acute Leukemias
July 1st 2000ASCO-STI-571, an investigational drug that has high activity in benign-phase chronic myelogenous leukemia (CML), also produces significant hematologic responses in patients with advanced-stage CML or acute forms of leukemia, Moshe Talpaz, MD, said at the 36th annual meeting of the American Society of Clinical Oncology (ASCO) in New Orleans.
Mylotarg Is Approved for Older AML Patients in First Relapse
June 1st 2000ASCO-Mylotarg (gemtuzumab ozogamicin) has received FDA approval for treatment of CD33-positive acute myelogenous leukemia (AML) in patients age 60 and older in first relapse who are poor candidates for cytotoxic therapy. The agent, manufactured by Wyeth-Ayerst, was approved as an orphan drug.
HCVAD/Transplant Promising for Mantle Cell Lymphoma
May 1st 2000NEW ORLEANS-The chemotherapy regimen HCVAD followed by stem cell transplantation yields high response and survival rates for patients with aggressive mantle cell lymphoma, Issa Khouri, MD, of the M.D. Anderson Cancer Center, reported at the 41st annual meeting of the American Society of Hematology (ASH).
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
March 1st 2000Researchers in Germany and Austria have found a way to achieve high survival rates in children with Hodgkin’s disease while reducing serious long-term side effects. Until now, children with Hodgkin’s disease have experienced high survival rates but
Rituximab/CHOP Induction Therapy in Newly Diagnosed Patients With Mantle Cell Lymphoma
March 1st 2000Mantle cell lymphoma (MCL) is a recently identified, aggressive, B-cell neoplasm that is incurable with current combination chemotherapy regimens. Novel therapeutic strategies are needed. MCLs express high levels of cell-surface CD20 and are
Rituximab in the Treatment of Gastrointestinal Mucosa-Associated Lymphoid Tissue Lymphoma
March 1st 2000Originally described in the 1980s, mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent, B-cell lymphoma that has been reclassified by the revised European-American Lymphoma (REAL) classification system as extranodal, marginal